Abbott Reports FreeStyle Libre Trial Results, Shows Significant Improvement in Glucose Control

Abbott announced results from the FreeDM2 randomized controlled trial showing that people using FreeStyle Libre continuous glucose monitoring technology had better glucose outcomes than those using traditional fingersticks. Improvements were achieved through participant-led self-management, guided by real-time CGM insights. Findings were presented at the 19th International Conference on Advanced Technologies & Treatments for Diabetes. At four months, participants using an Abbott FreeStyle Libre system for continuous glucose monitoring had a significantly greater reduction in HbA1c than the group using traditional finger sticks. They also spent about 2.5 more hours a day in a healthy glucose range. Participants were on basal insulin with either an SGLT2 inhibitor or a GLP-1 receptor agonist, indicating meaningful benefit even among people already on advanced glucose-lowering therapies. A separate interventional study from Italy, also being presented at ATTD, followed 88 adults with Type 2 diabetes using basal insulin in everyday clinical practice with an Abbott FreeStyle Libre system. After 3 months, participants had better average glucose levels, more time in a healthy glucose range, and improved quality of life.